GSK shelves cough drug acquired in $2B deal

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...
Nasdaq

Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials

(RTTNews) - Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential ...
The American Journal of Managed Care

A Review of Similarities and Differences Between 2 Different Cough Tests

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests. Researchers found the combination of the cough suppression test and the cough challenge ...